ARCHIVES

FDA cancer therapeutics review split among three units in reorganization.

This article is from The Cancer Letter archive.

Vol. 29 No. 37 | October 10, 2003

Download PDF Visit The Full Archive

Related Articles

Research Opportunities In Pancreas Cancer Described; Top Priority Set

December 21, 1973

In Brief: ACS Asks Removal Of Dollar Authorization Levels; FDA May Overrule Advisors On Estramustine

November 23, 1979

NCI Plans To Issue Frederick Operations Contract As Sole-Source To SAIC-Frederick Inc. For Up To 10 Years.

November 10, 2006

NCI Remains Exception To NIH Authority Over Scientific Counselors

January 27, 1995

NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not

July 3, 1981

Limb-Sparing Surgery May Not Offer Better Quality of Life

August 28, 2009